What is PTN's market cap?

$10.72M, based on the Nov 4 close of $6.02.

Does Palatin Technologies pay a dividend?

No regular cash dividend has been paid in the last year.

How much of PTN is sold short?

332.2K shares, 19.6% of float, as of Oct 15, 2026.

What sector is PTN in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · PTNHealthcarePharmaceuticals

Palatin Technologies, Inc. Common Stock (PTN)

$6.02+15.33%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$6.02▼ 45.47% in range

Nov 12, 2025Low $4.77 · High $28.00Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Palatin Technologies closed at $6.02 on Nov 4, up 15.33%, 78.5% below its 52-week closing high. Volume of 51.4K shares was 1.46× its 20-day average (above normal).

Split-adjusted performance: -36.0% over one month, -68.3% over six months.

In the quarter ended Jun 30, 2026, revenue was $300.77K, with a net margin of -1449.1%.

Short interest was 332.2K shares at the Oct 15 settlement, down 9.0% from the prior report (19.6% of float, 14.3 days to cover).

Market cap$10.7M1.8M shares

Revenue · quarter$300.8K—

Diluted EPS$-1.16—

P/E · TTM—P/S 0.8×

Net margin-1,449.1%Gross 100.0%

Dividend yieldNone

52-week range4.77 – 28.00−78.5% from high

Volume51.4K1.46× 20-day avg

Volatility · 60d112.9%Annualised

Short % of float19.6%14.3 days to cover

Net cash$7.5MCash $7.5M

Next earnings—Not scheduled

Split-adjusted performance

1W +18.0%1M −36.0%3M −23.5%6M −68.3%YTD −60.9%1Y —3Y +198.0%5Y −42.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum13

Revenue growth—

Net margin17

Value (low P/E)—

Size16

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short332.2K−9.0% vs prior

Days to cover14.3Settled Oct 15

% of float19.6%

Short vol. 10d43.9%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
PTNPalatin Technologies	$6.02	+15.33%	−68.3%	—	−1449.1%	—	$10.7M
RKTORocket One	$0.4422	−4.33%	—	—	—	—	$11.0M	Compare
ASBPAspire-Lakewood Holdings	$7.31	+0.55%	+31.0%	—	−2009.6%	—	$10.3M	Compare
PHIOPhio Pharmaceuticals	$0.8699	−3.67%	−24.4%	—	—	—	$10.1M	Compare
LSTALisata Therapeutics	$1.06	−2.75%	−67.5%	−100.0%	—	—	$11.5M	Compare
TVRDTvardi Therapeutics	$0.8614	+3.17%	−76.5%	—	—	—	$11.5M	Compare
CLRBCellectar Biosciences INC NEW	$1.23	−6.11%	−65.2%	—	—	—	$11.6M	Compare
BIVIBioVie	$1.34	−22.54%	−19.3%	—	—	—	$11.6M	Compare
BFRGBullfrog AI Holdings	$0.5263	+0.59%	−25.4%	+547.6%	−636.8%	—	$9.8M	Compare

News about Palatin Technologies

All news →

No recent articles focused on Palatin Technologies.

Quick answers

What does Palatin Technologies do?: Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential.
What is PTN's market cap?: $10.72M, based on the Nov 4 close of $6.02.
Does Palatin Technologies pay a dividend?: No regular cash dividend has been paid in the last year.
How much of PTN is sold short?: 332.2K shares, 19.6% of float, as of Oct 15, 2026.
What sector is PTN in?: Healthcare, in the Pharmaceuticals industry.

About Palatin Technologies

Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. It is also developing, dependent on resources for development activities, MC1R agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It has one operating segment life science.

HQ: Cranbury, NJ25 employeesListed Nov 4, 1993palatin.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology